Cerenis Therapeutics SA, which is developing drugs novel based on high density lipoprotein (HDL), so called good cholesterol, to treat cardiovascular and other metabolic diseases, has raised a further €10 million in a second close of its third round financing. This takes the total funds raised in the round to €50 million and the total raised to date by the company to €117 million.
Jean-Louis Dasseux, co-founder and CEO of Cerenis, said, “We are delighted to close this additional financing. Cerenis is now well positioned to continue its growth and HDL programme development.”
This financing will fund Phase II development of the lead Cerenis program, CER-001, an HDL-mimetic for the treatment of cardiovascular disease. It will also support the development of other new HDL therapies.
CER-001, is intended to rapidly regress atherosclerotic plaque in patients with Acute Coronary Syndrome.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
